France Épargne Corporate
IP and royalty financing for companies
France Épargne Corporate connects companies seeking to finance €20m or more with the private debt funds whose ticket size, instruments and sectors match their case. Transactions on pharmaceutical royalties reached an estimated $10.0bn in 2025.
Royalty financing in 2025
- $10.0bn
- of transactions on pharmaceutical royalties in 2025 (estimate)
- 21
- pharmaceutical royalty transactions of $500m or more since 2020 (count as of February 2026)
- $1.765bn
- notes that Concord issued in July 2025 against more than 1.3 million copyrights of its music catalogue
Transactions
Financings on intellectual property assets
Synthetic royalty
The company that develops or markets a product grants the funder a percentage of its future sales of that product in exchange for funding. The funder pays the money in tranches. Each tranche depends on clinical results, marketing approval or sales.
Sale of an existing royalty
A licensor receives a percentage of the sales made by its licensee. It sells all or part of these future flows for an upfront payment.
Secured term loan
The lender grants a senior secured loan alongside the royalty. The tranches become available after marketing approval and when sales thresholds are reached.
Growth financingMusic catalogue securitisation
The issuer places rated notes secured by the copyrights of a catalogue. The Concord notes issued in July 2025 have terms of 5, 7 and 10 years.
Pledge over patents and trademarks
The lender takes a pledge over the borrower’s patents or trademarks. It registers the pledge in the National Patent Register or the National Trademark Register. It then enforces the pledge against third parties.
Pledge over software
The pledge covers the exploitation right of the software. The lender registers the pledge in a special register of the INPI. It describes the scope of the security there. The source code is part of this scope.
Market
Transactions and security on intellectual property
| Transaction | Underlying | Amount | Terms |
|---|---|---|---|
| Revolution Medicines, synthetic royalty (June 2025) | Worldwide sales of daraxonrasib, a pancreatic cancer drug | Up to $1,250m | Five tranches of $250m, the first two mandatory, the next three at the borrower’s option |
| Revolution Medicines, secured term loan (June 2025) | Senior secured loan, tranches tied to approval and sales | Up to $750m | SOFR plus 5.75%, SOFR floor of 3.5%, maturity six years after the first drawdown |
| Concord, securitisation (July 2025) | Catalogue of more than 1.3 million copyrights valued at more than $5.1bn | $1,765m | Senior notes of 5, 7 and 10 years rated A+ (KBRA) and A2 (Moody’s) |
SOFR (Secured Overnight Financing Rate) is the overnight reference rate of the US dollar. Revolution Medicines draws the first tranche of the term loan after the FDA (Food and Drug Administration) approves daraxonrasib.
| Tranche | Up to $2bn | $2bn to $4bn | $4bn to $8bn |
|---|---|---|---|
| Tranche 1 | 2.55% | 1.50% | 0.60% |
| Tranche 2 | 2.00% | 1.00% | 0.40% |
| Tranche 3 | 1.50% | 0.80% | 0.40% |
| Tranche 4 | 1.00% | 0.75% | 0.50% |
| Tranche 5 | 0.75% | 0.50% | 0.50% |
| Total | 7.80% | 4.55% | 2.40% |
Rates are adjusted pro rata to the amount drawn on each tranche.
| Right | Form of the deed | Enforceability against third parties |
|---|---|---|
| Patent | In writing, on pain of nullity, for transfer and licence | Registration in the National Patent Register |
| Trademark | In writing, on pain of nullity, for transfer and pledge | Registration in the National Trademark Register |
| Software | In writing, on pain of nullity | Registration in the special register of the INPI, valid five years, renewable |
Questions
Frequently asked questions
- What is a synthetic royalty?
- A synthetic royalty is a contractual right to a percentage of a product’s sales, created for the funder in exchange for funding. In June 2025, Revolution Medicines obtained up to $1.25bn against a royalty on worldwide sales of daraxonrasib. The combined rate reaches 7.80% up to $2bn of annual sales, 4.55% from $2bn to $4bn and 2.40% from $4bn to $8bn, pro rata to the tranches drawn.
- How is a patent or a trademark pledged in France?
- The French Intellectual Property Code requires a written deed, on pain of nullity, for the transfer or the pledge of a trademark. Deeds that transfer or modify the rights attached to a patent become enforceable against third parties once registered in the National Patent Register kept by the INPI. Deeds on a trademark follow the same rule with the National Trademark Register. A third party that knew of the deed before acquiring its rights remains bound by it without registration.
- How is software pledged?
- Article L132-34 of the French Intellectual Property Code allows a pledge over the exploitation right of software. The parties put the agreement in writing. Without a written deed, the agreement is void. The creditor registers the pledge in a special register kept by the INPI. Without registration, the creditor cannot enforce it against third parties. The creditor describes the scope of the security there. The source code is part of this scope. Ranking follows the order of registration and a registration lapses after five years unless renewed.
- How large is the pharmaceutical royalty market?
- Transactions on pharmaceutical royalties reached an estimated $10.0bn in 2025. From 2020 to February 2026, 21 transactions each exceeded $500m. With a royalty sale, a biotech company keeps operational control of its programmes. It retains a larger share of their economic value than in a partnership with a large pharmaceutical group. The funding reduces the administrative work of such a partnership.
- How does a music catalogue securitisation work?
- Concord issued $1.765bn of senior notes in July 2025. A catalogue of more than 1.3 million copyrights, valued at more than $5.1bn, secures these notes. Their terms are 5, 7 and 10 years. KBRA rates the notes A+. Moody’s rates them A2. The proceeds repay the $1.65bn notes issued in 2022. It is the fourth securitisation of Concord.
- From what amount can a company request an introduction for intellectual property financing?
- France Épargne Corporate introduces companies whose financing need reaches €20m or more to private debt funds and other non bank lenders. The total amount requested against patents, trademarks or royalties must reach this threshold. The lender alone decides to lend. It sets the amount, the tranches, the rate and the security.
Contact
Request an introduction to lenders
Sources
- Royalty Pharma plc, rapport annuel 2025 (formulaire 10-K) déposé auprès de la SEC, février 2026
- Royalty Pharma, Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion, 24 juin 2025
- Apollo, Concord Closes $1.765 Billion ABS to Fuel Continued Growth, communiqué du 22 juillet 2025
- Code de la propriété intellectuelle, article L613-8, transmission et licence des droits attachés au brevet
- Code de la propriété intellectuelle, article L613-9, Registre national des brevets, version issue de la loi n° 2008-776 du 4 août 2008
- Code de la propriété intellectuelle, article L714-1, transmission et nantissement de la marque, version issue de l’ordonnance n° 2019-1169 du 13 novembre 2019
- Code de la propriété intellectuelle, article L714-7, Registre national des marques, version en vigueur depuis le 15 décembre 2019
- Code de la propriété intellectuelle, article L132-34, nantissement du droit d’exploitation des logiciels, version issue de la loi n° 94-361 du 10 mai 1994